DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
550 W. Jackson Blvd., Suite 1500	7/30/2018-8/10/2018*		
Chicago, IL 60661-4716 (312)353-5863 Fax:(312)596-4187	FEI NUMBER 3006572203		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	<u>.</u>		
Andrew J. Roseboom , Co-Owner and Pharma	cist-In-Charge		
FIRM NAME	STREET ADDRESS		
Dolan Central Illinois Compounding LLC dba Preckshot Professional Pharmacy	5832 N Knoxville Ave, Ste E		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Peoria, IL 61614-4300	Producer of Sterile and Non-Sterile Drug Products		

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1

Your facility was designed and/or operated in a way that permits poor flow of materials.

Specifically,

Materials are brought into the ISO 7 Buffer room directly from an unclassified area through(b) (4)

(b) (4) For example, your firm utilizes this material (b) (4) to transfer in sterile processing supplies such as (b) (4) syringes, sterile (b) (4)(b) (4) spray bottles, sterile wipes (b) (4) pharmaceutical grade (b) (4) and zip-lock bags.

I observed sterile production of Papaverine, Phentolamine, Alprostadil (15: 0.5: 25) in ML injectable, lot 07302018@18 for (b) (6) and Papaverine, Phentolamine, Alprostadil (25: 0.8: 20) in ML injectable, lot 07302018@17 for (b) (6) in your ISO 5 hood on 07/30/18.

OBSERVATION 2

Non-sterile bulk solutions are held for an extended period with no documentation to support the hold time.

Specifically,

Your firm prepares bulk stock solutions inside an uncertified hood and stores it inside a (b) (4) as an intermediary stock solution at (b) (4) for up to (d) days after processing without (b) (4). For example, your firm produced (b) (4) of Alprostadil stock solution, lot 07122018@9 (Beyond use date 08/26/18) on 07/12/18. According to your firm management on 08/09/18, you do not require your intermediary stock solution

AMENDMENT 1

SEE REVERSE OF THIS PAGE	Bei Y He, Investigato	Bel Y He investigator Styned By 2001878494 Daile Styned 08-10-2018 15 35	DATE ISSUED 8/10/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 1 of 4 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER 550 W. Jackson Blvd., Suite 1500 7/30/2018-8/10/2018* FEI NUMBER Chicago, IL 60661-4716 3006572203 (312)353-5863 Fax: (312)596-4187 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Andrew J. Roseboom , Co-Owner and Pharmacist-In-Charge FIRM NAME STREET ADDRESS Dolan Central Illinois Compounding LLC 5832 N Knoxville Ave, Ste E dba Preckshot Professional Pharmacy

to be (b) (4) prior to being(b) (4) for later use. Your firm utilized this lot of stock solution to produce the sterile products through (b) (4) in the ISO 5 hood on 07/12/18, 07/13/18, 07/16/18, 07/18/18, and 07/19/18.

TYPE ESTABLISHMENT INSPECTED

Products

Producer of Sterile and Non-Sterile Drug

RX	LOT	DRUG	FILLED	BUD
b) (6	07122018@12	Phentolamine, Alprostadil Injectable 0.83MG/16.66MG	07/12/18	08/09/18
	07132018@11	Papaverine, Phentolamine, Alprostadil Injectable	07/13/18	08/10/18
	07132018@9	Papaverine, Phentolamine, Alprostadil Injectable	07/13/18	08/10/18
	07132018@6	Alprostadil 20MCG/ML Aqueous SOLN	07/13/18	08/26/18
	07162018@9	Phentolamine, Alprostadil Injectable 0.83MG/16.66MG	07/16/18	08/13/18
	17162018@8		t.	
	07162018@8	Papaverine, Phentolamine, Alprostadil Injectable	07/16/18	08/13/18
	07162018@7	Papaverine, Phentolamine, Alprostadil Injectable	07/16/18	08/13/18
	07182018@9	Papaverine, Phentolamine, Alprostadil Injectable	07/18/18	08/15/18
	07182018@15	Papaverine, Phentolamine, Alprostadil Injectable	07/18/18	08/15/18
	07192018@7	Papaverine, Phentolamine, Alprostadil Injectable	07/19/18	08/16/18

OBSERVATION 3

CITY, STATE, ZIP CODE, COUNTR'

Peoria, IL 61614-4300

Your firm prepares multi-dose sterile drug products with an extended beyond use date without preservatives. Specifically,

AMENDMENT 1

SEE REVERSE OF THIS PAGE		Del Y He Investigator Signed by 2001878494 Date Signed 09-10-2018 15 35 15	B/10/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 2 of 4 PAGES

	LTH AND HUMAN SERVICES UG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
550 W. Jackson Blvd., Suite 1500	7/30/2018-8/10/2018*		
Chicago, IL 60661-4716 (312)353-5863 Fax:(312)596-4187	FEI NUMBER 3006572203		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	·		
Andrew J. Roseboom , Co-Owner and Pharma	cist-In-Charge		
FIRM NAME	STREET ADDRESS		
Dolan Central Illinois Compounding LLC dba Preckshot Professional Pharmacy	5832 N Knoxville Ave, Ste E		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Peoria, IL 61614-4300	Producer of Sterile and Non-Sterile Drug Products		

- Acetylcysteine Ophthalmic solutions are produced by your firm without preservatives. This ophthalmic solution is dispensed to your patients as a multi-dose sterile product with a beyond use date of 45 days in frozen/refrigerated conditions.
- ➤ Tacrolimus in Corn Oil NF Ophthalmic solutions are produced by your firm without preservatives. This ophthalmic solution is dispensed to your patients as a multi-dose sterile product with a beyond use date of 28 days in room temperature.

OBSERVATION 4

Disinfecting agents and cleaning pads used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

During sterile processing on 07/30/18, your Pharmacy Technician utilized non-sterile, low-shedding (b) (4) wipes sprayed with sterile (b) (4)(b) (4) to transfer sterile processing materials such as vials, syringes, and sterile (b) (4) spray bottles into the ISO 5 hood. I observed sterile production of Papaverine, Phentolamine, Alprostadil (15: 0.5: 25) in ML injectable, lot 07302018@18 for (b) (6) and Papaverine, Phentolamine, Alprostadil (25: 0.8: 20) in ML injectable, lot 07302018@17 for (b) (6) in your ISO 5 hood on 07/30/18.

OBSERVATION 5

AMENDMENT 1

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Bei Y He, Investigator	Bel Y He Investigator Signed by 2001878494 Signed 08-10-2018 15 35 15	8/10/2018
-----------------------------	---	--	-----------

PAGE 3 of 4 PAGES

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
	STRICT ADDRESS AND PHONE NUMBER		SPECTION		
	kson Blvd., Suite 1500 L 60661-4716		7/30/2018-8/10/2018* FEI NUMBER		
	863 Fax: (312) 596-4187		2203		
NAME AND TITLE OF INDIVIDUA					
	seboom , Co-Owner and Pharmac				
dba Preckshot	l Illinois Compounding LLC t Professional Pharmacy	5832 N Knoxville	e Ave, Ste E		
CITY, STATE, ZIP CODE, COUN		TYPE ESTABLISHMENT INSPECTED			
Peoria, IL 6	1614-4300	Producer of Ste Products	rile and Non-St	erile Drug	
Equipment was n	not disinfected prior to entering the asep	otic processing areas.			
Specifically,					
mop head to sani on 07/30/18. I ob injectable, lot 07:	Prior to sterile processing, your firm attached a pre-moistened sterile (b) (4) mop head to sanitize the ISO 5 hood. I observed the foam mop head to be discolored with black colored residues on 07/30/18. I observed sterile production of Papaverine, Phentolamine, Alprostadil (15: 0.5: 25) in ML injectable, lot 07302018@18 for (b) (6) and Papaverine, Phentolamine, Alprostadil (25: 0.8: 20) in ML injectable, lot 07302018@17 for (b) (6) in your ISO 5 hood on 07/30/18.				
*DATES OF F	NODECTION				
657 3	NSPECTION), 7/31/2018(Tue), 8/01/2018(Wed) , 8/10/2018(Fri)	, 8/02/2018(Thu), 8/02/2018(Thu)	03/2018(Fri), 8/07	/2018(Tue),	
l .					
l .					
	22				
AMENDMENT 1					
	EMPLOYEE(S) SIGNATURE			DATE ISSUED	
SEE REVERSE OF THIS PAGE	Bei Y He, Investigator		Bel Y He Investigator Signed By 2001878494 Date Signed 08-10-2018 15 35 15	8/10/2018	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL OBSERVATI	ONS	PAGE 4 of 4 PAGES	